New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds

With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients.